Trial · NCT01953432
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
NCT01953432, Phase 2, Completed, VA Office of Research and Development; results first posted 2020-02-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse. Trials, record NCT01953432. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01953432
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
- NCT number
- NCT01953432
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 43 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Cocaine Dependence
- Interventions
- Doxazosin, Placebo
- First posted
- 2013-10-01
- Last updated
- 2020-02-20
- Results first posted
- 2020-02-20
- Limitations and caveats
- There was a protocol amendment and the primary outcome measure was changed. The planned analysis was revised to a Bayesian approach to ensure more robust analysis of data given smaller sample size.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Cocaine-positive Urines | Up to 12 weeks, or for the duration of the participant's involvement in the study | Over period of 12 weeks with 43 participants total (Doxazosin group = 22; Placebo group = 21), the overall percentage of cocaine positive urines per treatment group |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Cocaine-positive Urines | Up to 12 weeks, or for the duration of the participant's involvement in the study | Study population was comprised of 43 cocaine-dependent individuals who met inclusion criteria for this study. | percentage of cocaine-positive urines | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Cocaine-positive Urines | Doxazosin | 67.6 | percentage of cocaine-positive urines | ||
| Percentage of Cocaine-positive Urines | Placebo | 69 | percentage of cocaine-positive urines |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Doxazosin | 22 | |
| Overall Study | STARTED | Placebo | 21 | |
| Overall Study | COMPLETED | Doxazosin | 8 | |
| Overall Study | COMPLETED | Placebo | 6 | |
| Overall Study | NOT COMPLETED | Doxazosin | 14 | |
| Overall Study | NOT COMPLETED | Placebo | 15 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Doxazosin | 2 | 22 | 2 |
| other | Nausea | Gastrointestinal disorders | Placebo | 1 | 21 | 1 |
| other | Dry mouth | General disorders | Doxazosin | 1 | 22 | 1 |
| other | Dry mouth | General disorders | Placebo | 1 | 21 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Doxazosin | 0 | 22 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 2 | 21 | 2 |
| other | Lightheadedness | General disorders | Doxazosin | 1 | 22 | 1 |
| other | Lightheadedness | General disorders | Placebo | 1 | 21 | 1 |
| other | Cold/Viral Illness | Infections and infestations | Doxazosin | 1 | 22 | 1 |
| other | Cold/Viral Illness | Infections and infestations | Placebo | 1 | 21 | 1 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Doxazosin | 0 | 22 |
| Total, all-cause mortality | Placebo | 0 | 21 |
| Total, other adverse events | Doxazosin | 8 | 22 |
| Total, other adverse events | Placebo | 5 | 21 |
| Total, serious adverse events | Doxazosin | 0 | 22 |
| Total, serious adverse events | Placebo | 0 | 21 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| IK2CX000946 | Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse | SHORTER, DARYL I | MICHAEL E DEBAKEY VA MEDICAL CENTER | Veterans Affairs | 2014 to 2017 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Doxazosin vs Placebo: deaths from any cause | Trial comparisons |
| Doxazosin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01953432
GET https://conductscience.org/api/trials/v1/NCT01953432/events?page=2